Efficacy and safety of ascending doses of moxidectin against Strongyloides stercoralis infections in adults: a randomised, parallel-group, single-blinded, placebo-controlled, dose-ranging, phase 2a trial-Reference-Cited by-同舟云学术

Efficacy and safety of ascending doses of moxidectin against Strongyloides stercoralis infections in adults: a randomised, parallel-group, single-blinded, placebo-controlled, dose-ranging, phase 2a trial

Published:2021-08 Issue:8 Volume:21 Page:1151-1160
ISSN:1473-3099
Container-title:The Lancet Infectious Diseases
language:en
Short-container-title:The Lancet Infectious Diseases

Author:

Hofmann Daniela,Sayasone Somphou,Sengngam Khanpaseuth,Chongvilay Bounthunh,Hattendorf Jan,Keiser Jennifer

Publisher

Elsevier BV

Subject

Infectious Diseases

Reference30 articles.

1. Strongyloides stercoralis: global distribution and risk factors;Schär;PLoS Negl Trop Dis,2013

2. A public health response against Strongyloides stercoralis: time to look at soil-transmitted helminthiasis in full;Krolewiecki;PLoS Negl Trop Dis,2013

3. Strongyloidiasis—the most neglected of the neglected tropical diseases?;Olsen;Trans R Soc Trop Med Hyg,2009

4. Strongyloides hyperinfection syndrome: an emerging global infectious disease;Marcos;Trans R Soc Trop Med Hyg,2008

5. Ivermectin versus albendazole or thiabendazole for Strongyloides stercoralis infection;Henriquez-Camacho;Cochrane Database Syst Rev,2016

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Helminthic Diseases: Intestinal Nematode Infection;International Encyclopedia of Public Health;2025

2. Human Strongyloides stercoralis infection;Journal of Microbiology, Immunology and Infection;2024-08

3. Moxidectin versus Ivermectin in the prevention and treatment of acute and chronic experimental trichinellosis;Experimental Parasitology;2024-07

4. Efficacy and safety of moxidectin compared with ivermectin against Strongyloides stercoralis infection in adults in Laos and Cambodia: a randomised, double-blind, non-inferiority, phase 2b/3 trial;The Lancet Infectious Diseases;2024-02

5. Efficacy and safety of moxidectin against strongyloidiasis;The Lancet Infectious Diseases;2024-02